Swedbank AB Has $561,000 Stock Position in Moderna, Inc. $MRNA

Key Points

• Swedbank AB has reduced its holdings in Moderna, Inc. by 79.1%, now owning 19,802 shares valued at $561,000 as of the latest SEC filing.
• Voloridge Investment Management LLC significantly increased its stake in Moderna by 335.6% during the fourth quarter, now holding 2,590,831 shares valued at $107.7 million.
• Moderna reported a quarterly loss of ($2.13) EPS, surpassing estimates, and its revenue of $142 million was down 41.1% compared to the same quarter last year.

Swedbank AB lessened its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 79.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 19,802 shares of the company's stock after selling 74,883 shares during the quarter. Swedbank AB's holdings in Moderna were worth $561,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Invesco Ltd. boosted its stake in shares of Moderna by 17.5% in the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock valued at $166,801,000 after purchasing an additional 877,162 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Moderna by 0.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,597,236 shares of the company's stock valued at $101,982,000 after purchasing an additional 11,270 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Moderna by 5.4% in the 1st quarter. Northern Trust Corp now owns 3,119,626 shares of the company's stock valued at $88,441,000 after purchasing an additional 160,572 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Moderna by 12.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company's stock valued at $74,557,000 after purchasing an additional 285,662 shares during the last quarter. Finally, Voloridge Investment Management LLC boosted its stake in shares of Moderna by 335.6% in the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock valued at $107,727,000 after purchasing an additional 1,996,003 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Moderna Price Performance

MRNA stock traded down $0.43 during midday trading on Friday, reaching $25.02. 8,147,398 shares of the company were exchanged, compared to its average volume of 10,890,682. The business has a 50-day moving average price of $27.73 and a two-hundred day moving average price of $28.03. Moderna, Inc. has a one year low of $23.15 and a one year high of $67.96. The firm has a market capitalization of $9.73 billion, a price-to-earnings ratio of -3.33 and a beta of 1.93.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm had revenue of $142.00 million during the quarter, compared to analysts' expectations of $116.26 million. During the same period in the previous year, the business posted ($3.33) earnings per share. The company's revenue for the quarter was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on MRNA shares. JPMorgan Chase & Co. set a $26.00 price target on shares of Moderna in a research report on Friday, August 1st. Barclays cut their price target on shares of Moderna from $40.00 to $31.00 and set an "equal weight" rating on the stock in a research report on Monday, August 4th. Wells Fargo & Company reiterated an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Cowen initiated coverage on shares of Moderna in a research report on Sunday, July 13th. They issued a "hold" rating on the stock. Finally, William Blair restated a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fourteen have assigned a Hold rating and four have issued a Sell rating to the company's stock. According to MarketBeat, Moderna has a consensus rating of "Hold" and an average price target of $41.81.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.